1.  88
    Ethical, Legal and Social Aspects of Brain-Implants Using Nano-Scale Materials and Techniques.Francois Berger, Sjef Gevers, Ludwig Siep & Klaus-Michael Weltring - 2008 - NanoEthics 2 (3):241-249.
    Nanotechnology is an important platform technology which will add new features like improved biocompatibility, smaller size, and more sophisticated electronics to neuro-implants improving their therapeutic potential. Especially in view of possible advantages for patients, research and development of nanotechnologically improved neuro implants is a moral obligation. However, the development of brain implants by itself touches many ethical, social and legal issues, which also apply in a specific way to devices enabled or improved by nanotechnology. For researchers developing nanotechnology such issues (...)
    Direct download (4 more)  
    Export citation  
    My bibliography   4 citations  
  2.  1
    Use of Genetic Data, Employment and Insurance: An International Perspective.Sjef Gevers - 1993 - Bioethics 7 (2-3):126-134.
  3.  8
    Physician Assisted Suicide: New Developments in the Netherlands.Sjef Gevers - 1995 - Bioethics 9 (3):309–312.
    Until recently, physician assisted suicide was dealt with on the same basis as active voluntary euthanasia in the Netherlands. Over the last years, several cases relating to assistance in suicide of mental patients did raise specific issues, not addressed so far in the debate on euthanasia. One of these cases resulted in a Supreme Court decision. The paper summarizes this decision and comments on it from a legal point of view.
    Direct download (5 more)  
    Export citation  
    My bibliography  
  4.  4
    Third Trimester Abortion for Fetal Abnormality.Sjef Gevers - 1999 - Bioethics 13 (3-4):306-313.
    Direct download (3 more)  
    Export citation  
    My bibliography  
  5.  1
    Your Biobank, Your Doctor? The Right to Full Disclosure of Population Biobank Findings.Jasper Bovenberg, Tineke Meulenkamp, Ellen Smets & Sjef Gevers - 2009 - Genomics, Society and Policy 5:55-79.
    The advent of personal genomics companies offering direct translation of scientific data into personal health information, calls into question traditional policies to refuse disclosure of such scientific data to research participants. This seems especially true for population biobanks, as they collect not only genotype information but also associated phenotype information, and thus may be in a unique position to translate their scientific findings into personal health information for their participants. Disclosure of such information seems mandated by the expectations raised by (...)
    Direct download  
    Export citation  
    My bibliography